Novartis To Spin-Off Sandoz as Stand-Alone, Public Company

  My readers may recall that I disclosed (see my post athttps://blog.sstrumello.com/2022/07/novartis-sandoz-is-back-in-insulin.html for details) some information buried in Novartis ' July 20, 2022 quarterly earnings release, when buried on page 21 of the company ' s 64-page Q2& half-year 2022 financial statement, when we finally learned that the company ' s planned insulin biosimilars first announced in late 2018 were still very much in development. In fact, the Gan& Lee-manufactured insulin glargine U-100, insulin aspart U-100 and insulin lispro U-100 bisimilars were indeed still happening and may actually be further along in development than we ever realized. Sandoz has chosen a co-development partner offshore, specifically Beijing China-basedGan& Lee Pharmaceuticals Co., Ltd., which Sandoz originally stated was " a leading insulin supplier headquartered in China with more than 20 years ' experience in insulins and production capacity with attractive cost of goods sold (COGS) structures " .It is believed Sandoz, much like such companies as Biocon as well as Lannett/HEC Pharma and evenCivica/GeneSys Biologics all opted to use an offshore manufacturing partner so they were in a position to actually pay Pharmacy Benefit Managers ( " PBM ' s " ) multi-billion dollar, legally-exempted kickbacks used to secure exclusive formulary placement (the exclusivity part may actually be illegal). Civica is unique among them in that the company has gone on re...
Source: Scott's Web Log - Category: Endocrinology Tags: 2022 Biosimilar biosimilars Gan & Lee insulin Novartis Sandoz Source Type: blogs